Funded Biotechnology Startups in Denmark
A clear size outlier appears at the top of the most recent biotech rounds: Galecto raised $275M on 2026-02-10, dwarfing the next-largest disclosed rounds v…
A clear size outlier appears at the top of the most recent biotech rounds: Galecto raised $275M on 2026-02-10, dwarfing the next-largest disclosed rounds visible here (Hemab at $157M on 2025-11-02 and Zealand Pharma at $1.0B on 2024-06-25). That same “tail” shows up at the low end as well: the smallest disclosed amount in the rows is $240K (ENZIDIA, 2026-03-16), while several undisclosed rounds sit in between (e.g., Minerva Imaging on 2025-06-10; Ousia Pharma on 2025-05-06).
Deal timing clusters are also noticeable: multiple rounds land within a tight late-January to mid-March 2026 window (e.g., ENZIDIA 2026-03-16, Gefjon Pharma 2026-03-03, SynuCa Therapeutics 2026-03-02, Galecto 2026-02-10). Geographically, Copenhagen/Hovedstaden dominates the addresses—Copenhagen, Frederiksberg, and nearby suburbs appear repeatedly (e.g., Octarine Bio in Copenhagen on 2026-01-22; Chromologics in Søborg on 2025-11-22; Antag Therapeutics in Copenhagen on 2024-12-04). Stage labeling is mixed, with “Series Unknown” appearing frequently (19 of 50 rows), and “undisclosed” amounts appearing 7 times across the date range spanning 2022-02-15 (NMD Pharma) through 2026-03-16 (ENZIDIA).
Most recent rounds
50 shownRelated listings
Frequently asked
What are the biggest disclosed biotech rounds in this Denmark list, and how extreme is the top end?
The largest disclosed amount is Zealand Pharma’s $1.0B on 2024-06-25. Galecto’s $275M on 2026-02-10 is the next-largest disclosed figure in the 2026 entries and still sits far above most other disclosed rounds such as Hemab ($157M on 2025-11-02) and ADCendo ($135M on 2024-11-25).
Do the rounds cluster in time near the most recent quarter?
Yes. Between 2026-02-10 and 2026-03-16, multiple disclosed rounds appear in succession: Galecto ($275M, 2026-02-10), Octarine Bio ($6M, 2026-01-22), Gefjon Pharma ($2M, 2026-03-03), SynuCa Therapeutics ($2M, 2026-03-02), and ENZIDIA ($240K, 2026-03-16).
Which stage labels dominate, and where do “unknown” or missing amounts show up?
“Series Unknown” is the most common label, appearing in 19 of 50 rows (for example Galecto 2026-02-10 is “Series Unknown,” as are many others like EvodiaBio on 2025-12-19 for $7M). Separately, “undisclosed” amounts occur 7 times, including Minerva Imaging (undisclosed, 2025-06-10), Ousia Pharma (undisclosed, 2025-05-06), and Neurescue (undisclosed, 2025-02-17).
Is there a geography hub effect, or are investments spread across many Danish cities?
The list is heavily concentrated in the Copenhagen-area. Examples include Copenhagen (Octarine Bio 2026-01-22 for $6M; Antag Therapeutics 2024-12-04 for $84M; Hemab 2025-11-02 for $157M), Frederiksberg (Gefjon Pharma, 2026-03-03 for $2M), and nearby suburbs like Søborg (Chromologics, 2025-11-22 for $8M) and Hørsholm (ExpreS2ion, 2025-10-06 for $1M).
Are there outliers on the low end worth flagging for deal-size targeting?
ENZIDIA’s $240K on 2026-03-16 is the smallest disclosed amount in the rows and is much smaller than other late-2026/early-2026 disclosed rounds such as Gefjon Pharma ($2M on 2026-03-03) and SynuCa Therapeutics ($2M on 2026-03-02). Another low disclosed point is Evaxion Biotech at $80K on 2025-06-03, which still sits above the $240K level.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.